These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33488408)

  • 1. Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance.
    Li K; Liao Y; Yang Z; Yang C; Chen M; Wu X; Gan Z
    Front Psychiatry; 2020; 11():529672. PubMed ID: 33488408
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: A mirror image retrospective study.
    Caliskan AM; Calisir S; Caliskan S; Arslan M; Inanli I; Eren I
    Asian J Psychiatr; 2020 Dec; 54():102457. PubMed ID: 33271736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
    Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM).
    Vieta E; Angst J; Reed C; Bertsch J; Haro JM;
    J Affect Disord; 2009 Nov; 118(1-3):118-23. PubMed ID: 19269690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).
    Parellada E; Bioque M; Serrano M; Herrera B; García Dorado M;
    Int J Psychiatry Clin Pract; 2018 Sep; 22(3):191-199. PubMed ID: 29161951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.
    Fu DJ; Turkoz I; Walling D; Lindenmayer JP; Schooler NR; Alphs L
    Schizophr Res; 2018 Feb; 192():185-193. PubMed ID: 28454922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM).
    Bellivier F; Yon L; Luquiens A; Azorin JM; Bertsch J; Gerard S; Reed C; Lukasiewicz M
    Bipolar Disord; 2011 Jun; 13(4):377-86. PubMed ID: 21843277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
    Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
    J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Long-Acting Injectable Antipsychotics in Adolescents.
    Pope S; Zaraa SG
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):391-4. PubMed ID: 27028966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting.
    Di Lorenzo R; Cameli M; Piemonte C; Bolondi M; Landi G; Pollutri G; Spattini L; Moretti V; Ferri P
    Nord J Psychiatry; 2018 Apr; 72(3):214-220. PubMed ID: 29278968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.